Skip to main content

Advertisement

Log in

A systematic review of humoral immune responses against tumor antigens

  • Review
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

This review summarizes studies on humoral immune responses against tumor-associated antigens (TAAs) with a focus on antibody frequencies and the potential diagnostic, prognostic, and etiologic relevance of antibodies against TAAs. We performed a systematic literature search in Medline and identified 3,619 articles on humoral immune responses and TAAs. In 145 studies, meeting the inclusion criteria, humoral immune responses in cancer patients have been analyzed against over 100 different TAAs. The most frequently analyzed antigens were p53, MUC1, NY-ESO-1, c-myc, survivin, p62, cyclin B1, and Her2/neu. Antibodies against these TAAs were detected in 0–69% (median 14%) of analyzed tumor patients. Antibody frequencies were generally very low in healthy individuals, with the exception of few TAAs, especially MUC1. For several TAAs, including p53, Her2/neu, and NY-ESO-1, higher antibody frequencies were reported when tumors expressed the respective TAA. Antibodies against MUC1 were associated with a favorable prognosis while antibodies against p53 were associated with poor disease outcome. These data suggest different functional roles of endogenous antibodies against TAAs. Although data on prediagnostic antibody levels are scarce and antibody frequencies for most TAAs are at levels precluding use in diagnostic assays for cancer early detection, there is some promising data on achieving higher sensitivity for cancer detection using panels of TAAs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kamradt T, Mitchison NA (2001) Tolerance and autoimmunity. N Engl J Med 344:655–664

    Article  PubMed  CAS  Google Scholar 

  2. Fonseca C, Dranoff G (2008) Capitalizing on the immunogenicity of dying tumor cells. Clin Cancer Res 14:1603–1608

    Article  PubMed  CAS  Google Scholar 

  3. Smyth MJ, Godfrey DI, Trapani JA (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2:293–299

    Article  PubMed  CAS  Google Scholar 

  4. Turk MJ, Wolchok JD, Guevara-Patino JA et al (2002) Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol Rev 188:122–135

    Article  PubMed  CAS  Google Scholar 

  5. Delves PJ, Roitt IM (2000) The immune system. First of two parts. N Engl J Med 343:37–49

    Article  PubMed  CAS  Google Scholar 

  6. Houghton AN (1994) Cancer antigens: immune recognition of self and altered self. J Exp Med 180:1–4

    Article  PubMed  CAS  Google Scholar 

  7. Jäger E, Jäger D, Knuth A (2003) Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 106:817–820

    Article  PubMed  CAS  Google Scholar 

  8. Renkvist N, Castelli C, Robbins PF et al (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3–15

    Article  PubMed  CAS  Google Scholar 

  9. Finn OJ (2008) Cancer immunology. N Engl J Med 358:2704–2715

    Article  PubMed  CAS  Google Scholar 

  10. Rescigno M, Avogadri F, Curigliano G (2007) Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 1776:108–123

    PubMed  CAS  Google Scholar 

  11. Himoto T, Kuriyama S, Zhang JY et al (2005) Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol 27:1079–1085

    PubMed  CAS  Google Scholar 

  12. Zhang JY, Casiano CA, Peng XX et al (2003) Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12:136–143

    PubMed  CAS  Google Scholar 

  13. Zhang JY, Megliorino R, Peng XX et al (2007) Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 46:107–114

    Article  PubMed  CAS  Google Scholar 

  14. Mensdorff-Pouilly S, Verstraeten AA, Kenemans P et al (2000) Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 18:574–583

    Google Scholar 

  15. Croce MV, Isla-Larrain MT, Capafons A et al (2001) Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women. Breast Cancer Res Treat 69:1–11

    Article  PubMed  CAS  Google Scholar 

  16. Kurtenkov O, Klaamas K, Rittenhouse-Olson K et al (2005) IgG immune response to tumor-associated carbohydrate antigens (TF, Tn, alphaGal) in patients with breast cancer: impact of neoadjuvant chemotherapy and relation to the survival. Exp Oncol 27:136–140

    PubMed  CAS  Google Scholar 

  17. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S et al (2007) Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 46:316–323

    Article  PubMed  CAS  Google Scholar 

  18. Hamanaka Y, Suehiro Y, Fukui M et al (2003) Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 103:97–100

    Article  PubMed  CAS  Google Scholar 

  19. Ralhan R, Nath N, Agarwal S et al (1998) Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. Clin Cancer Res 4:2147–2152

    PubMed  CAS  Google Scholar 

  20. Looi K, Megliorino R, Shi FD et al (2006) Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep 16:1105–1110

    PubMed  CAS  Google Scholar 

  21. Koziol JA, Zhang JY, Casiano CA et al (2003) Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9:5120–5126

    PubMed  CAS  Google Scholar 

  22. Ralhan R, Arora S, Chattopadhyay TK et al (2000) Circulating p53 antibodies, p53 gene mutational profile and product accumulation in esophageal squamous-cell carcinoma in India. Int J Cancer 85:791–795

    Article  PubMed  CAS  Google Scholar 

  23. Richards ER, Devine PL, Quin RJ et al (1998) Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol Immunother 46:245–252

    Article  PubMed  CAS  Google Scholar 

  24. Graves CR, Robertson JF, Murray A et al (2005) Malignancy-induced autoimmunity to MUC1: initial antibody characterization. J Pept Res 66:357–363

    Article  PubMed  CAS  Google Scholar 

  25. Green JA, Mudenda B, Jenkins J et al (1994) Serum p53 auto-antibodies: incidence in familial breast cancer. Eur J Cancer 30A:580–584

    Article  PubMed  CAS  Google Scholar 

  26. Davidoff AM, Iglehart JD, Marks JR (1992) Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 89:3439–3442

    Article  PubMed  CAS  Google Scholar 

  27. Komiya T, Hirashima T, Takada M et al (1997) Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 17:3721–3724

    PubMed  CAS  Google Scholar 

  28. Kressner U, Glimelius B, Bergstrom R et al (1998) Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. Br J Cancer 77:1848–1851

    PubMed  CAS  Google Scholar 

  29. Hammel P, Leroy-Viard K, Chaumette MT et al (1999) Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer. Int J Cancer 81:712–718

    Article  PubMed  CAS  Google Scholar 

  30. Bourhis J, Lubin R, Roche B et al (1996) Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst 88:1228–1233

    Article  PubMed  CAS  Google Scholar 

  31. Lechpammer M, Lukac J, Lechpammer S et al (2004) Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int J Colorectal Dis 19:114–120

    Article  PubMed  Google Scholar 

  32. Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777–1788

    PubMed  CAS  Google Scholar 

  33. Jäger E, Stockert E, Zidianakis Z et al (1999) Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: correlation with clinical events. Int J Cancer 84:506–510

    Article  PubMed  Google Scholar 

  34. Maio M, Coral S, Sigalotti L et al (2003) Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. J Clin Endocrinol Metab 88:748–754

    Article  PubMed  CAS  Google Scholar 

  35. Stockert E, Jäger E, Chen YT et al (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349–1354

    Article  PubMed  CAS  Google Scholar 

  36. Goodell V, Waisman J, Salazar LG et al (2008) Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther 7:449–454

    Article  PubMed  CAS  Google Scholar 

  37. Karsten U, Mensdorff-Pouilly S, Goletz S (2005) What makes MUC1 a tumor antigen? Tumour Biol 26:217–220

    Article  PubMed  CAS  Google Scholar 

  38. Reuschenbach M, Waterboer T, Wallin KL et al (2008) Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers. Int J Cancer 123:2626–2631

    Article  PubMed  CAS  Google Scholar 

  39. Akcakanat A, Kanda T, Koyama Y et al (2004) NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 54:95–100

    Article  PubMed  CAS  Google Scholar 

  40. Fossa A, Berner A, Sophie DF et al (2004) NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 59:440–447

    Article  PubMed  CAS  Google Scholar 

  41. Wadle A, Kubuschok B, Imig J et al (2006) Serological immune response to cancer testis antigens in patients with pancreatic cancer. Int J Cancer 119:117–125

    Article  PubMed  CAS  Google Scholar 

  42. Chang JT, Wong FH, Liao CT et al (2004) Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem 50:1261–1264

    Article  PubMed  CAS  Google Scholar 

  43. Fishman P, Merimski O, Baharav E et al (1997) Autoantibodies to tyrosinase: the bridge between melanoma and vitiligo. Cancer 79:1461–1464

    Article  PubMed  CAS  Google Scholar 

  44. Disis ML, Pupa SM, Gralow JR et al (1997) High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15:3363–3367

    PubMed  CAS  Google Scholar 

  45. Nakamura H, Hinoda Y, Nakagawa N et al (1998) Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J Gastroenterol 33:354–361

    Article  PubMed  CAS  Google Scholar 

  46. Traina A, Agostara B, Marasa L et al (2006) HER2/neu expression in relation to clinicopathologic features of breast cancer patients. Ann N Y Acad Sci 1089:159–167

    Article  PubMed  CAS  Google Scholar 

  47. Ferretti G, Felici A, Papaldo P et al (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19:56–62

    Article  PubMed  Google Scholar 

  48. Nesterova M, Johnson N, Cheadle C et al (2006) Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 1762:398–403

    PubMed  CAS  Google Scholar 

  49. Kim JH, Herlyn D, Wong KK et al (2003) Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9:4782–4791

    PubMed  CAS  Google Scholar 

  50. Qin S, Qiu W, Ehrlich JR et al (2006) Development of a “reverse capture” autoantibody microarray for studies of antigen-autoantibody profiling. Proteomics 6:3199–3209

    Article  PubMed  CAS  Google Scholar 

  51. Philip R, Murthy S, Krakover J et al (2007) Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer. J Proteome Res 6:2509–2517

    Article  PubMed  CAS  Google Scholar 

  52. Lu H, Goodell V, Disis ML (2008) Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 7:2168

    Article  CAS  Google Scholar 

  53. Ran Y, Hu H, Zhou Z et al (2008) Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res 14:2696–2700

    Article  PubMed  CAS  Google Scholar 

  54. Abendstein B, Marth C, Müller-Holzner E et al (2000) Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 88:1432–1437

    Article  PubMed  CAS  Google Scholar 

  55. Mayerhofer K, Tempfer C, Kucera E et al (1999) Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Anticancer Res 19:875–878

    PubMed  CAS  Google Scholar 

  56. Volkmann M, Sinn HP, Gaugel D et al (2002) Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression. Oncology 63:297–305

    Article  PubMed  CAS  Google Scholar 

  57. Tang R, Ko MC, Wang JY et al (2001) Humoral response to p53 in human colorectal tumors: a prospective study of 1, 209 patients. Int J Cancer 94:859–863

    Article  PubMed  CAS  Google Scholar 

  58. Lai CL, Tsai CM, Tsai TT et al (1998) Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res 4:3025–3030

    PubMed  CAS  Google Scholar 

  59. Qiu LL, Hua PY, Ye LL et al (2007) The detection of serum anti-p53 antibodies from patients with gastric carcinoma in China. Cancer Detect Prev 31:45–49

    Article  PubMed  CAS  Google Scholar 

  60. Sangrajrang S, Arpornwirat W, Cheirsilpa A et al (2003) Serum p53 antibodies in correlation to other biological parameters of breast cancer. Cancer Detect Prev 27:182–186

    Article  PubMed  CAS  Google Scholar 

  61. Jezersek B, Rudolf Z, Novakovic S (2001) The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients. Oncol Rep 8:77–81

    PubMed  CAS  Google Scholar 

  62. Shimada H, Takeda A, Arima M et al (2000) Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677–1683

    Article  PubMed  CAS  Google Scholar 

  63. Vogl FD, Stickeler E, Weyermann M et al (1999) p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology 57:324–329

    Article  PubMed  CAS  Google Scholar 

  64. Scott N, Sagar P, Stewart J et al (1991) p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 63:317–319

    PubMed  CAS  Google Scholar 

  65. Qin Z, Richter G, Schüler T et al (1998) B cells inhibit induction of T cell-dependent tumor immunity. Nat Med 4:627–630

    Article  PubMed  CAS  Google Scholar 

  66. Gumus E, Erdamar S, Demirel G et al (2004) Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol 11:1070–1077

    Article  PubMed  Google Scholar 

  67. Manson LA (1991) Does antibody-dependent epitope masking permit progressive tumour growth in the face of cell-mediated cytotoxicity? Immunol Today 12:352–355

    Article  PubMed  CAS  Google Scholar 

  68. Tan TT, Coussens LM (2007) Humoral immunity, inflammation and cancer. Curr Opin Immunol 19:209–216

    Article  PubMed  CAS  Google Scholar 

  69. Imai H, Ochs RL, Kiyosawa K et al (1992) Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 140:859–870

    PubMed  CAS  Google Scholar 

  70. Trivers GE, Cawley HL, DeBenedetti VM et al (1995) Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 87:1400–1407

    Article  PubMed  CAS  Google Scholar 

  71. Lubin R, Schlichtholz B, Teillaud JL et al (1995) p53 antibodies in patients with various types of cancer: assay, identification, and characterization. Clin Cancer Res 1:1463–1469

    PubMed  CAS  Google Scholar 

  72. Schlichtholz B, Legros Y, Gillet D et al (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52:6380–6384

    PubMed  CAS  Google Scholar 

  73. Lubin R, Zalcman G, Bouchet L et al (1995) Serum p53 antibodies as early markers of lung cancer. Nat Med 1:701–702

    Article  PubMed  CAS  Google Scholar 

  74. Schlichtholz B, Tredaniel J, Lubin R et al (1994) Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 69:809–816

    PubMed  CAS  Google Scholar 

  75. Angelopoulou K, Diamandis EP, Sutherland DJ et al (1994) Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 58:480–487

    Article  PubMed  CAS  Google Scholar 

  76. Hammel P, Boissier B, Chaumette MT et al (1997) Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 40:356–361

    PubMed  CAS  Google Scholar 

  77. Korangy F, Ormandy LA, Bleck JS et al (2004) Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma. Clin Cancer Res 10:4332–4341

    Article  PubMed  CAS  Google Scholar 

  78. Yonezawa S, Goto M, Yamada N et al (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8:3329–3341

    Article  PubMed  CAS  Google Scholar 

  79. Parmigiani RB, Bettoni F, Grosso DM et al (2008) Antibodies against the cancer-testis antigen CTSP-1 are frequently found in prostate cancer patients and are an independent prognostic factor for biochemical-recurrence. Int J Cancer 122:2385–2390

    Article  PubMed  CAS  Google Scholar 

  80. Bachelot T, Ratel D, Menetrier-Caux C et al (2006) Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 94:1066–1070

    Article  PubMed  CAS  Google Scholar 

  81. Hirasawa Y, Kohno N, Yokoyama A et al (2000) Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 161:589–594

    PubMed  CAS  Google Scholar 

  82. Shimada H, Kuboshima M, Shiratori T et al (2007) Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol 30:97–103

    PubMed  CAS  Google Scholar 

  83. Boon T, van der BP (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725–729

    Article  PubMed  CAS  Google Scholar 

  84. Finn OJ (2007) Human tumor immunology at the molecular divide. J Immunol 178:2615–2616

    PubMed  CAS  Google Scholar 

  85. Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 7:565–577

    PubMed  CAS  Google Scholar 

  86. Agrawal B, Krantz MJ, Reddish MA et al (1998) Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2. Nat Med 4:43–49

    Article  PubMed  CAS  Google Scholar 

  87. Gourevitch MM, Mensdorff-Pouilly S, Litvinov SV et al (1995) Polymorphic epithelial mucin (MUC-1)-containing circulating immune complexes in carcinoma patients. Br J Cancer 72:934–938

    PubMed  CAS  Google Scholar 

  88. Cramer DW, Titus-Ernstoff L, McKolanis JR et al (2005) Conditions associated with antibodies against the tumor-associated antigen MUC1 and their relationship to risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev 14:1125–1131

    Article  PubMed  CAS  Google Scholar 

  89. Menard S, Casalini P, Campiglio M et al (2004) Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci 61:2965–2978

    Article  PubMed  CAS  Google Scholar 

  90. Jager D, Knuth A (2005) Antibodies and vaccines—hope or illusion? Breast 14:631–635

    Article  PubMed  Google Scholar 

  91. Montgomery RB, Makary E, Schiffman K et al (2005) Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res 65:650–656

    PubMed  CAS  Google Scholar 

  92. Disis ML, Schiffman K (2001) Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28:12–20

    Article  PubMed  CAS  Google Scholar 

  93. Chapman CJ, Murray A, McElveen JE et al (2008) Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax 63:228–233

    Article  PubMed  CAS  Google Scholar 

  94. Yamamoto A, Shimizu E, Ogura T et al (1996) Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer 69:283–289

    Article  PubMed  CAS  Google Scholar 

  95. Chen Y, Lin P, Qiu S et al (2007) Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol 30:1137–1144

    PubMed  CAS  Google Scholar 

  96. Ersvaer E, Zhang JY, McCormack E et al (2007) Cyclin B1 is commonly expressed in the cytoplasm of primary human acute myelogenous leukemia cells and serves as a leukemia-associated antigen associated with autoantibody response in a subset of patients. Eur J Haematol 79:210–225

    Article  PubMed  CAS  Google Scholar 

  97. Shi FD, Zhang JY, Liu D et al (2005) Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 63:252–258

    Article  PubMed  CAS  Google Scholar 

  98. Disis ML, Calenoff E, McLaughlin G et al (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16–20

    PubMed  CAS  Google Scholar 

  99. McNeel DG, Nguyen LD, Storer BE et al (2000) Antibody immunity to prostate cancer associated antigens can be detected in the serum of patients with prostate cancer. J Urol 164:1825–1829

    Article  PubMed  CAS  Google Scholar 

  100. Chapman C, Murray A, Chakrabarti J et al (2007) Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 18:868–873

    Article  PubMed  CAS  Google Scholar 

  101. Snijdewint FG, Mensdorff-Pouilly S, Karuntu-Wanamarta AH et al (1999) Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 48:47–55

    Article  PubMed  CAS  Google Scholar 

  102. Türeci O, Mack U, Luxemburger U et al (2006) Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett 236:64–71

    Article  PubMed  CAS  Google Scholar 

  103. Nakamura S, Nouso K, Noguchi Y et al (2006) Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma. J Gastroenterol Hepatol 21:1281–1285

    Article  PubMed  CAS  Google Scholar 

  104. Hogdall EV, Hogdall CK, Blaakaer J et al (2002) P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. APMIS 110:545–553

    Article  PubMed  Google Scholar 

  105. Kaur J, Srivastava A, Ralhan R (1997) Serum p53 antibodies in patients with oral lesions: correlation with p53/HSP70 complexes. Int J Cancer 74:609–613

    Article  PubMed  CAS  Google Scholar 

  106. Castelli M, Cianfriglia F, Manieri A et al (2001) Anti-p53 and anti-heat shock proteins antibodies in patients with malignant or pre-malignant lesions of the oral cavity. Anticancer Res 21:753–758

    PubMed  CAS  Google Scholar 

  107. Volkmann M, Muller M, Hofmann WJ et al (1993) The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the alpha-fetoprotein status. Hepatology 18:559–565

    PubMed  CAS  Google Scholar 

  108. Coomber D, Hawkins NJ, Clark M et al (1996) Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer. J Cancer Res Clin Oncol 122:757–762

    Article  PubMed  CAS  Google Scholar 

  109. Lubin R, Schlichtholz B, Bengoufa D et al (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53:5872–5876

    PubMed  CAS  Google Scholar 

  110. Angelopoulou K, Stratis M, Diamandis EP (1997) Humoral immune response against p53 protein in patients with colorectal carcinoma. Int J Cancer 70:46–51

    Article  PubMed  CAS  Google Scholar 

  111. Creaney J, McLaren BM, Stevenson S et al (2001) p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression. Br J Cancer 84:52–56

    Article  PubMed  CAS  Google Scholar 

  112. Labrecque S, Naor N, Thomson D et al (1993) Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 53:3468

    PubMed  CAS  Google Scholar 

  113. Selter H, Schmidt G, Villena-Heinsen C et al (1999) Humoral immune response to p21WAF1/CIP1 in tumor patients, non-tumorous patients and healthy blood donors. Cancer Lett 137:151–157

    Article  PubMed  CAS  Google Scholar 

  114. Zhang JY, Zhu W, Imai H et al (2001) De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol 125:3–9

    Article  PubMed  CAS  Google Scholar 

  115. Zhang JY, Chan EK, Peng XX et al (2001) Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol 100:149–156

    Article  PubMed  CAS  Google Scholar 

  116. Yagihashi A, Asanuma K, Kobayashi D et al (2005) Detection of autoantibodies to livin and survivin in Sera from lung cancer patients. Lung Cancer 48:217–221

    Article  PubMed  Google Scholar 

  117. Yagihashi A, Ohmura T, Asanuma K et al (2005) Detection of autoantibodies to survivin and livin in sera from patients with breast cancer. Clin Chim Acta 362:125–130

    Article  PubMed  CAS  Google Scholar 

  118. Yagihashi A, Asanuma K, Kobayashi D et al (2005) Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma. Autoimmunity 38:445–448

    Article  PubMed  CAS  Google Scholar 

  119. Anderson KS, Ramachandran N, Wong J et al (2008) Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 7:1490–1499

    Article  PubMed  CAS  Google Scholar 

  120. Soling A, Plugge EM, Schmitz M et al (2007) Autoantibodies to the inhibitor of apoptosis protein survivin in patients with brain tumors. Int J Oncol 30:123–128

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Miriam Reuschenbach.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (PDF 110 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reuschenbach, M., von Knebel Doeberitz, M. & Wentzensen, N. A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother 58, 1535–1544 (2009). https://doi.org/10.1007/s00262-009-0733-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-009-0733-4

Keywords

Navigation